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Background: Human Leukocyte Antigen (HLA) class I restricted Cytotoxic T Lymphocytes (CTLs) exert substantial
evolutionary pressure on HIV-1, as evidenced by the reproducible selection of HLA-restricted immune escape mutations
in the viral genome. An escape mutation from tyrosine to phenylalanine at the 135th amino acid (Y135F) of the HIV-1
nef gene is frequently observed in patients with HLA-A*24:02, an HLA Class I allele expressed in ~70% of Japanese
persons. The selection of CTL escape mutations could theoretically result in the de novo creation of novel epitopes,
however, the extent to which such dynamic “CTL epitope switching” occurs in HIV-1 remains incompletely known.
Results: Two overlapping epitopes in HIV-1 nef, Nef126-10 and Nef134-10, elicit the most frequent CTL responses
restricted by HLA-A*24:02. Thirty-five of 46 (76%) HLA-A*24:02-positive patients harbored the Y135F mutation in their
plasma HIV-1 RNA. Nef codon 135 plays a crucial role in both epitopes, as it represents the C-terminal anchor for
Nef126-10 and the N-terminal anchor for Nef134-10. While the majority of patients with 135F exhibited CTL responses
to Nef126-10, none harboring the “wild-type” (global HIV-1 subtype B consensus) Y135 did so, suggesting that
Nef126-10 is not efficiently presented in persons harboring Y135. Consistent with this, peptide binding and limiting
dilution experiments confirmed F, but not Y, as a suitable C-terminal anchor for HLA-A*24:02. Moreover, experiments
utilizing antigen specific CTL clones to recognize endogenously-expressed peptides with or without Y135F indicated
that this mutation disrupted the antigen expression of Nef134-10. Critically, the selection of Y135F also launched the
expression of Nef126-10, indicating that the latter epitope is created as a result of escape within the former.
Conclusions: Our data represent the first example of the de novo creation of a novel overlapping CTL epitope as a
direct result of HLA-driven immune escape in a neighboring epitope. The robust targeting of Nef126-10 following
transmission (or in vivo selection) of HIV-1 containing Y135F may explain in part the previously reported stable
plasma viral loads over time in the Japanese population, despite the high prevalence of both HLA-A*24:02 and
Nef-Y135F in circulating HIV-1 sequences.Background
Cytotoxic T lymphocytes (CTLs) are key players in the
immune control of Human Immunodeficiency Virus 1
(HIV-1), as they recognize virally-derived peptide epi-
topes presented by HLA class I molecules on the in-
fected cell surface [1,2]. Over the course of infection* Correspondence: aikichi@ra3.so-net.ne.jp
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unless otherwise stated.however, HIV-1 mutations arise within the infected indi-
vidual, notably in targeted CTL epitopes, that allow the
virus to escape immune recognition by CTLs. Importantly,
despite the hypermutability of HIV-1, these immune
escape mutations often arise in a stereotypical manner
[3,4] that is highly predictable based on the specific
HLA class I molecules expressed by the host [5-8].
Although selection of HLA-associated mutations in
HIV-1 is driven by immune pressure, these amino acid
substitutions sometimes result in the induction of a
de novo immune response in which the mutant epitope
is recognized by a TCR associated with a different CTL
subset [7,9]. What is less well-characterized is the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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result in the de novo creation of novel CTL epitopes
nearby, that could subsequently be targeted by CTL
in vivo (in a manner similar to the continual exposure
of novel antibody epitopes in HIV-1 envelope as a conse-
quence of escape from earlier humoral responses [10]).
Here, we demonstrate such a dynamic phenomenon of
“CTL epitope switching” as a direct result of CTL escape
from HLA-A*24:02.
We reported previously that the substitution from
tyrosine to phenylalanine (Y135F) at the 135th amino acid
of the HIV-1 nef gene is frequently observed in patients
with HLA-A*24:02, an HLA Class I allele expressed
in ~70% of Japanese persons [4,11]. Our observation
that Y135F appeared to be an escape mutation was later
confirmed [12]. In order to examine the influence of
HIV-1 mutations on the strength of various epitope-
specific CTL responses, we studied CTL epitopes re-
stricted by HLA-A*24:02 in relatively conserved regions
of the HIV-1 genome. Our results indicate that Nef-
Y135F, selected to escape recognition of a well-described
HLA-A*24:02-restricted CTL epitope in this viral protein,
results in the creation of another HLA-A*24:02 epitope
immediately upstream. To our knowledge, our findings
represent the first evidence of immune escape-driven
“epitope switching” in HIV-1 infection.
Results
Identification of immunodominant CTL responses
restricted by HLA-A*24:02
Forty-six HLA-A*24:02-positive patients with HIV-1 in-
fection were studied. Forty-four were infected through
unprotected sexual intercourse and 2 were hemophiliacs.
Forty-five were infected with subtype B except one was
infected with subtype AG. The median plasma viral load
(pVL) was 4.11 (range 2.26 to 5.36) log 10 copies/ml, and
the median CD4 cell count was 395 (range 120 to 1,035)
cells/μl. To determine which published HLA-A*24:02-
restricted CTL epitopes are most frequently recognized
among persons expressing this allele, IFN-γ ELISpot
assays were performed using expanded PBMCs. Due to
limited PBMC numbers, 11 published A*24:02-restricted
CTL epitopes in the relatively conserved gag, pol and nef
regions [13-15] were selected for investigation. Pub-
lished optimal epitopes were used for the assay. The
response rate against Nef134-10 was highest (80.4%),
followed by Nef126-10 (50.0%), Gag28-9 (40.0%) and
Pol496-9 (28.3%), while limited (<10%) or no responses
were observed in the other epitopes (Figure 1A, B). Of
note, Nef126-10 and Nef134-10 overlap each other by 2
amino acids (Figure 1A).
We next analyzed patient plasma HIV RNA amino
acid sequences within the Nef126-10–Nef134-10 regions
(Table 1). The great majority of patients (35/46 = 76.1%)had a tyrosine (Y) to phenylalanine (F) mutation
(Y135F) at Nef codon 135 (Nef135F) while eight patients
(8/46 = 17.4%) had the global consensus subtype B resi-
due at this position (Nef135Y). Two were Nef135L and
one was Nef135W. These results were consistent with
our earlier findings [4]. Intriguingly, none of the eight
patients with Nef135Y exhibited a Nef126-10-specific
response, while all of them exhibited a Nef134-10-
specific response (p < 0.001, Fisher’s exact test) (Figure 1C,
left). Of the 35 patients harboring Nef135F, 23 (65.7%)
and 28 (80.0%) responded to Nef126-10 and Nef134-
10, respectively (Figure 1C, right) (p = 0.2823, Fisher’s
exact test).
Dramatic improvement in the HLA-binding affinity of
Nef126-10 following mutation of the C-terminal anchor
residue
To clarify the relationship between Y135F and peptide-
specific responses, we examined HLA-binding affinity
of the wild type and mutant peptides using in vitro
peptide-HLA binding assays (Figure 2A). In context of the
Nef134-10 epitope, the mutant Y135F peptide (represent-
ing position 2, the N-terminal anchor of this epitope;
Nef134-10(2F)) was almost as effective as the “wild type”
Nef134-10 (Nef134-10(wt)) peptide in binding to HLA-
A*24:02. In contrast, in context of the Nef126-10 epitope,
the mutant Y135F peptide (representing position 10, the
C-terminal anchor of this epitope), dramatically improved
its binding to HLA-A*24:02. The presence of threonine
(T) at the 8th position (Nef126-10(8T10F)), representing
Nef mutation I133T, did not significantly affect epitope-
HLA binding compared to the wild type isoleucine (I)
(Nef126-10(8I10F)). These results are compatible with
previous reports identifying Y or F as possible N-terminal
anchors for HLA-A*24:02, but only F as a possible C-
terminal anchor [16,17].
We then examined the effect of the mutations on
epitope recognition using CTL clones established from
patients with HIV-1 infection. 293FT-A24DRm-CY0
cells pulsed with different dilutions of peptides were co-
cultured with CTL cell clones. The Nef134-10-specific
CTL clone H27-9 produced IFN-γ almost equally well
in response to Nef134-10(wt) peptides or to Nef134-10
(2F) peptides (Figure 2B, left). In contrast, the Nef126-
10-specific CTL clone I30-1 produced IFN-γ only at high
concentrations of the wild-type Nef126-10(wt) peptide,
whereas mutant peptides Nef126-10(8I10F) and Nef126-
10(8T10F) induced strong responses at very low peptide
concentration (Figure 2B, right). These results were con-
sistent with peptide-HLA binding assays suggesting that
the I133T mutation did not have much effect on re-
cognition of the epitope-HLA complex by the Nef126-10-
specific CTL clone I30-1. Moreover, the results were
consistent with the observation that the presence of
Figure 1 The association between the two overlapping epitopes and the Y135F mutation. (A) HIV-1 map of representative proteins and
the locations of HLA-A*24:02-restricted epitopes used in this study are shown (arrow). The positional relation and the sequence information
around Nef126-10 and Nef134-10 epitopes are also shown. (B) Immune responses to 11 epitopes were assessed by IFN-γ ELISpot assay by using
expanded PBMCs from 46 HIV-1 patients. Epitope names below the chart indicate peptides used in the assay; [Protein][Location(HXB2 number-
ing)]-[Amino acid length]. Each point represents the average SFU of duplicate wells after subtraction of background in each individual. Each stick
represents response rate in 46 individuals. (C) The Nef126-10/Nef134-10-specific response rates among individuals harboring either Nef135Y or
Nef135F were assessed. Black bars indicate number of responders to each epitope, and white bars for non-responders.
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Nef126-10 peptide to HLA-A*24:02 (Figure 2A).CTL responses against the endogenously expressed
epitopes
In order to examine whether intracellularly-derived Nef
protein could still be targeted by peptide-specific CTLs,
we constructed nef-minigene expression vectors, pmNef
(wt)-hRluc-EGFP, pmNef(135F)-hRluc-EGFP, and pmNef
(133T135F)-hRluc-EGFP, for the generation of polypep-
tides encompassing the Nef126-10 and Nef134-10 epi-
topes (Figure 3A). The vectors encoded EGFP as a
transfection marker, as well as the Renilla Luciferase
(Rluc) gene hooked to the mini-nef gene by a GlyGlyGly-
GlySer linker. Rluc activity served as a quantitative refer-
ence for the expression of the mini-nef polypeptide.
Each vector was transfected into 293FT-A24DRm-CY0
cells. Rluc activities indicated that three types of nef-minigenes were expressed well and to comparable levels
(Figure 3B).
We and others reported previously that Y135F is a
processing mutation, as CTL responses could be induced
to mutant epitopes via peptide-pulsing, but not via
intracellularly-expressed polypeptide [4,12,18]. Consist-
ent with the previous results, Nef134-10-specific re-
sponses by CTL clone H27-9 were induced by the wild
type minigene, but diminished to minimal levels by the
presence of Y135F or I133T/Y135F (Figure 3C, left).
By contrast, Nef126-10-specific responses by CTL
clone I30-1 were provoked dramatically by the presence
of Nef135F. Specifically, the Nef126-10-specific CTL
clone I30-1 showed much higher responses to antigen-
presenting cells transfected with the 133I/135F or 133T/
135F minigene than Nef134-10-specific CTL clone H27-9.
The I30-1 responses to minigenes encoding I versus T at
the Nef133 position did not substantially differ (Figure 3C,
right). In contrast, I30-1 responses to the wild type
Table 1 Amino acid sequences (Nef126-143) of plasma
HIV-1 in 46 patients
Groupa Amino acid sequenceb Frequency (number)c
Consensus B NYTPGPGIRYPLTFGWCF





















aPatients were partitioned into three groups, Nef135Y (135Y), Nef135F (135F),
or others, according to their amino acid information at the Nef135 position.
bMiddle column shows amino acid sequence of the Nef126-143 region. The
same amino acids as the subtype B consensus sequence are indicated by dots.
Differences compared to the subtype B consensus sequence are indicated by
the corresponding letters.
cRight column indicates frequency (and number) of individuals exhibiting the
stated sequence. Subtotal frequency (and number) of each group is italicized.
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These results suggest that wild-type Nef126-10 peptide
was not expressed as an epitope on the surface of the
antigen-presenting cells when expressed endogenously,
but Nef126-10 containing 135F (regardless of variation at
position 133) was efficiently expressed. In turn, these
in vitro results (Figure 2 and 3) strongly suggest that a
novel mechanism, i.e. “epitope switching” was taking place
after the selection of the Y135F mutation in vivo (Figure 1).
Namely, selection of Y135F facilitates escape from CTL re-
sponses targeting the first epitope (Nef134-10), but simul-
taneously results in the creation of another epitope
upstream (Nef126-10).
“Epitope switching” during the clinical course of HIV-1
infection
Among 8/46 patients in the IMSUT cohort who initially
harbored the “wild type” (global consensus B) Y135residue within the Nef134-10 epitope, we identified one
patient who subsequently selected 135F, followed by
133T, over a period of 12 months. We performed IFN-γ
ELISpot assays on PBMCs expanded from corresponding
frozen longitudinal samples (Figure 4A). Before the mu-
tated viruses became the majority, specific responses to
Nef134-10(wt) were the most prominent, followed by
responses to Nef134-10(2F) (Figure 4B, left). Import-
antly, no Nef126-10-specific responses were observed at
these time points. After plasma viruses were replaced by
viruses with 133T/135F, robust responses against Nef126-
10(8I10F) and Nef126-10(8T10F) were observed, while
responses against Nef126-10(wt) were detected only at
high peptide concentrations (Figure 4B, right). These
results were consistent with the results in vitro using
CTL clones (Figure 2B, right), and support the in vivo
presentation of Nef126-10 only after selection of Y135F.
Of interest, responses against Nef134-10 peptides de-
creased but remained detectable after the selection of
135F and 133T/135F mutations.
Coupled selection of Nef135F and Nef133T mutants
in vivo
We investigated the correlation between Nef135F and
Nef133T in silico in two other independent cohorts. In a
large cohort of antiretroviral-naïve patients chronically
infected with subtype B HIV-1 in British Columbia,
Canada (British Columbia HOMER cohort), positive
correlations between Nef135F and Nef133T (Odds ratio:
11.3), as well as between Nef135Y and Nef133I (Odds
ratio: 16.3) were observed (Figure 5A, all p < 0.0001).
Furthermore, in a multicenter longitudinal acute/early
infection cohort comprising 16 HLA-A*24:02-express-
ing persons infected with subtype B HIV-1, selection of
Nef135F preceded that of Nef133T by a short duration
(Figure 5B). The median times to Y135F and I133T se-
lection were 220 and 236 days, respectively, a difference
that was not statistically significant.
The correlation between the magnitude of Nef126-10
(8I10F) or Nef126-10(8T10F)-specific response and pVL
was assessed in 24 IMSUT cohort participants for
whom Nef126-10(8I10F) and Nef126-10(8T10F) responses
(measured by IFN-γ ELISpot) and pVL at the correspond-
ing time point, were available (Figure 5C). Interestingly,
Nef126-10(8I10F)-specific but not Nef126-10(8T10F)-
specific responses were inversely correlated with pVL,
suggesting that responses to the former, but not the latter,
contribute to in vivo immune control.
Crystal structures of Nef126-10 epitopes presented on
HLA-A*24:02
In order to examine the impact of these mutations on
epitope structure, we solved the crystal structures of
HLA-A24/Nef126-10(8I10F) and HLA-A24/Nef126-10
Figure 2 Epitope characterization. (A) Binding affinity of each peptide to HLA-A*24:02 was tested by using T2-A24 cell line. All peptides except
negative control peptide, VPLDKDFRKY, which might not bind to HLA-A*24:02, show HLA-A*24:02 binding in the peptide concentration of 10−4 M. Each
point and bar represents the average and the standard deviation of normalized MFI from three independent experiments. (B) 293FT-A24DRm-CY0 cells
were pulsed with serially diluted peptides and co-cultured with CTL clones specific to Nef134-10 (H27-9) or Nef126-10 (I30-1). Epitope recognition was
determined by normalizing quantity of IFN-γ secretion. For normalization, all values were divided by IFN-γ secretion with wild type peptide
concentration of 9 μM. Neither clone showed specificity to the negative control, Gag28-9 peptide (KYKLKHIVW) a binder of HLA-A*24:02. Each
point and bar show average and standard deviation of three independent experiments.
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(Figure 6A top and bottom; Additional file 1: Figure
S1A, B). Superposition of the Nef126-10(8I10F) and
Nef126-10(8T10F) peptide structures showed almost
similar backbone atoms, with root mean square devi-
ation of 0.307 Å, but conformational differences were
found at P6 (131P) and P9 (134R) residues. The side
chains of P6 and P9 residues in the Nef126-10(8I10F)
and Nef126-10(8T10F) epitopes had poor electron dens-
ities in spite of structures being at modestly higher reso-
lution (Additional file 1: Figure S1C, D). In addition, the
B-factors for the central portions (P5-P7) of each pep-
tide (41.5 Å2 for the Nef126-10(8I10F) and 46.2 Å2 for
Nef126-10(8T10F)) were higher than for overall pep-
tides (24.1 Å2 for Nef126-10(8I10F) and 33.2 Å2 for
Nef126-10(8T10F)). These results indicated a flexibility
of the central portion and P9 residue in both peptides,
accounting for the structural difference observed.
The side chains of P8-Ile and P8-Thr protruded from,
rather than being buried within, the antigen-bindingcleft of HLA-A*24:02, suggesting the P8 residue could
be involved in the contact with TCR (Figure 6A bottom).
Therefore, different TCRs could be favored by the pres-
ence of either hydrophobic P8-I or hydrophilic P8-T at
the interface of a TCR-HLA-A*24:02/Nef126-10. If this
is the case, different TCR repertoires would be selected
by Nef126-10(8I10F) or Nef126-10(8T10F), suggesting
Nef-I133T as a possible immune escape mutation that
alters the in vivo repertoire of CTL recognizing this
epitope.
Immune responses against Nef126-10 epitopes
We compared the epitope-specific immune responses
between two groups of individuals: those whose plasma
viruses were 133I/135F (n = 4) or 133T/135F (n = 10).
Ex vivo IFN-γ ELISpot assays using PBMCs and Nef126-
10(8I10F) or Nef126-10(8T10F) revealed that 0 of 4
patients with Nef126-10(8I10F) viruses had Nef126-10
(8T10F)-specific responses (Figure 6B). Nine out of 10
patients with Nef126-10(8T10F) viruses exhibited specific
Figure 3 Recognition of endogenously derived epitope. (A) Vector construction. The vector expresses EGFP as a transfection marker and a
fusion protein that consists of mini-Nef gene coding 31 amino acids of Nef123-Nef153 region and GlyGlyGlyGlySer linker and renilla luciferase.
The 133I/135F and 133T/135F mutant vectors as well as wild type vector were constructed. Mini-Nef sequence that corresponds to the actual Nef
gene is shown. (B) By measuring luciferase activity, quantity of the generated mini-Nef was assessed. No significant differences in mini-Nef generation
between wild type, 135F and 133T/135F were observed. Each stick and bar indicates average and standard deviation of three independent
experiments. (C) The vector transfected cells were incubated with either H27-9 or I30-1, and IFN-γ secretion was quantified by ELISA and normalized to
determine the epitope recognition. For normalization, each value was divided by IFN-γ secretion with wild type peptide concentration of 9 μM. Mock
as well as mGag, transfected with mGag(wt)-hRluc-EGFP, were measured as negative controls. Each stick and bar indicates average and standard
deviation of three independent experiments. The significance was calculated by unpaired Student’s t-test; **, p < 0.01; ***, p < 0.001.
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retained the response specific against Nef126-10(8I10F).
These results strongly suggested that the I133T mutation
induced a new subset of CD8+ T cells capable of recogniz-
ing Nef126-10(8T10F) (p = 0.005, Fisher’s exact test).
Functional avidity has been reported as a correlate of
CTL selective pressure [19,20]. As such, we analyzed
functional avidities of Nef126-10-specific CTLs. Nine in-
dividuals harboring 133T/135F were analyzed by limiting
dilution (Figure 6C). Nef126-10(8I10F)-specific CTL
responses showed significantly higher avidities compared
to those against Nef126-10(8T10F). Taken together with
the observation that pVL correlated inversely with the
magnitude of Nef126-10(8I10F)-specific, but not Nef126-
10(8T10F)-specific, responses (Figure 5C), these results
suggest that the new subset of CD8+ T cells elicited fol-
lowing selection of I133T exert less immune pressure onthe 133T mutant compared to the “wild-type” I133. The
hypothesis that Nef-I133T is an A*24-driven escape
mutation is additionally supported by numerous HLA-
association studies in HIV subtype B-infected popula-
tions including Japan, which consistently demonstrate
highly significant associations between A*24 and Nef-
I133T [4,8,21,22].
Discussion
HLA-A*24:02 is highly prevalent among East Asians in-
cluding Japanese [11]. In an effort to identify immuno-
dominant CTL epitopes presented by HLA-A*24:02, we
observed that the two most frequently-recognized
epitopes lay in Nef and overlapped each other by two
amino acids. Nef codon 135 is critical to both epitopes,
as it represents the N-terminal anchor for the down-
stream epitope Nef134-10, and the C-terminal anchor
Figure 4 Longitudinal analysis in one individual. (A) Time courses of the surrogate markers are shown. CD4+ T cell count (left axis, white
circle) and pVL (right axis, black circle) are plotted on the chart. Each arrow indicates the earliest time point when the sequence above the arrow
was observed. (B) IFN-γ ELISpot assay was performed by using serially diluted peptide set and expanded PBMCs. Two time points were tested for
the assay. At the earlier point, 2000/9/4, the patient harbored wild type sequence around the Nef126-10/Nef134-10 region, and at the latter point,
2003/3/20, the sequence displayed 133T/135F. Mutants as well as wild type peptides of Nef126-10 or Nef134-10 epitopes were used in the assay.
Each point represents the average SFU of duplicate wells after subtraction of background, and each error bar shows standard deviation.
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epitope Nef134-10, the Y-to-F mutation (Y135F) at the
second position is observed at high frequencies in circulat-
ing HIV-1 sequences in Japan – in fact it represents the
consensus at this position in Japan - presumably as a result
of high HLA-A*24:02 prevalence in the population [4,23].
Our experiments using a Nef134-10-specific CTL clone
and a minigene corroborated the earlier observation that
the Y135F mutation disrupts antigen processing of the
Nef134-10 epitope (Figure 3C) [4,12]. Importantly, while
the majority of patients with Y135F responded to the
upstream epitope Nef126-10, none of the patients with
the wild-type sequence responded to this epitope. Con-
sistent with this observation, results of the peptide
binding (Figure 2A) and limiting dilution experiments
using antigen-specific CTLs (Figure 2B) were compat-
ible with the previous reports indicating that F, but not
Y, could serve as a C-terminal anchor [16,17]. Also con-
sistent with this observation is that the 2nd position of
Nef126-10 is Y, a strong N-terminal anchor amino acid
for HLA-A*24:02. Taken together, in a process similar
to the ongoing exposure of novel antibody epitopes in
HIV-1 envelope as a consequence of escape from earlierhumoral responses [10], our results demonstrate that an
analogous phenomenon also occurs with CTL responses:
in this case a novel A*24:02-restricted “epitope switch”
from Nef134-10 to Nef126-10, as a result of immune-
driven escape at a single Nef codon.
We also showed that Nef residues I133T and Y135F are
highly significantly linked in vivo. Nef126-10 emerges as a
CTL epitope by the introduction of the Y135F mutation.
Though I133T has previously been identified as an
HLA-A*24:02-associated polymorphism in statistical asso-
ciation studies [4,8,21,22,24,25], its mechanism remained
unknown. Our data strongly suggest that I133T is
HLA-A*24:02-restricted escape mutation whose mechan-
ism of action is alteration of the in vivo CTL repertoire
capable of recognizing the HLA-bound epitope. Although
the sample size was limited, patients with 133I/135F
viruses did not exhibit responses to Nef126-10(8T10F)
(Figure 6B). These results, together with studies of a pa-
tient whose plasma viral sequences shifted from wild-type
to 133T/135F, strongly suggest that immune pressures
selected an I-to-T substitution at Nef ’s 133rd position.
IFN-γ ELISpot assays showed that Nef126-10(8I10F)-
specific but not Nef126-10(8T10F)-specific responses
Figure 5 Relevance of I133T mutation to Y135F and its impact on CTL responses. (A) The cross-sectional analysis of the co-variation
relationship between Nef codons 133 and 135. Nef codons containing gaps or amino acid mixtures were excluded from analysis, leaving 941 and
924 sequences for analysis of codon pairs 135F/133T and 135Y/133I, respectively. (B) Kaplan-Meier plot of the emergence of Y135F and I133T
mutations in a multicenter longitudinal acute/early infection cohort comprising 16 HLA-A*24:02-expressing persons. (C) Within 24 patients who
harboring 133I/135F or 133T/135F mutant, correlation between the magnitude of peptide-specific response and pVL was examined. Peptide-specific
response was determined by using ex vivo IFN-γ ELISpot assay with frozen PBMCs. Each point is plotted according to the average SFU of
duplicate wells and the measured pVL at the sampling point. Statistical significance of the correlation between the magnitude and pVL was
calculated by Spearman’s rank correlation.
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former had significantly higher functional avidities
(Figure 6C). These findings therefore suggest a TCR-
mediated mechanism underlying HLA-A*24:02-mediated
escape via I133T. Although higher functional avidity is a
hallmark of CTLs with stronger selective pressure [19,20],
further studies are needed to confirm that the I133T
mutation alleviates immune pressures directed on the
Nef126-10 epitope.
Crystal structures of peptide-HLA showed that the side
chain of the 133rd residue (P8 residue in the Nef126-10
epitope) protruded from the peptide-binding cleft presum-
ably providing a feature of the Nef126-10 epitope to the
TCRs (Figure 6A). The shorter side chain of T compared
to I might make the Nef126-10(8T10F) less accessible to
TCR than the Nef126-10(8I10F) epitope. Considering the
similarity of the structures, the absence of the T cell reper-
toire against the Nef126-10(8T10F) epitope in the patients
with 133I/135F viruses is an enigma. The suggested struc-
tural flexibility of the central portion (P5-P7) and P9 of
the Nef126-10 epitope may be relevant here.A key remaining question is why the Y135F mutation
is repeatedly selected by A*24:02, given that a conse-
quence of this escape is the introduction of another
A*24:02 epitope immediately upstream. We offer the
following hypothesis. In studies of HIV-1 infected popu-
lations around the globe, the association between HLA-
A*24:02 and Nef-135F consistently ranks among the
strongest in the HIV proteome [8,21], including in Japan
where F (rather than the global subtype B consensus Y)
represents the consensus at this position [4,22]. Indeed,
a recent international cohort study revealed an odds
ratio of >28 and a p-value of 8x10−118 for this association
[21]. The extraordinary magnitude of this association indi-
cates that Nef-135 is under similarly extraordinary selec-
tion pressure by A*24 in vivo - presumably due to highly
effective CTL responses against the Nef134–10 epitope.
The benefits to HIV of evading A*24-mediated recogni-
tion of Nef134–10 presumably outweigh its substantial
negative consequences to the virus, which in this case in-
clude the creation of the adjacent Nef126-10 epitope. That
Nef126-10 is targeted by less than 70% of A*24-expressing
Figure 6 Impact of I133T mutation on the structures of pHLA and responding T cell subsets. (A) Top; Side view of structures of the
Nef126-10(8I10F) (colored purple) and Nef126-10(8T10F) (colored green) is shown. Superimposition is based on the HLA-A*24:02 peptide binding
domain. Water molecules are represented in blue and yellow spheres for the Nef126-10(8I10F) and Nef126-10(8T10F) epitopes, respectively. The
number of peptide residues is labeled in black through P1 to P10. The HLA-A*24:02 is represented as a dark grey (Nef126-10(8T10F) and light grey
cartoon. (B) The presence of the responses to each peptide was examined by ex vivo ELISpot assay. A pair of sticks, Nef126-10(8I10F) (purple) and
Nef126-10(8T10F) (green), represents the average SFU of duplicate wells to each peptide in one patient. Four individuals on the left side harbored
133I/135F mutant and 10 individuals on the right side harbored 133T/135F mutant. (C) Functional avidity curve was drawn for 9 subjects who
harbored Nef133T/135F sequence. From the curve, SD50 was calculated and projected in this chart. Nef126-10(8I10F)-specific CTL responses (purple)
showed significantly higher functional avidity compared to Nef126-10(8T10F) (green). Each point represents functional avidity for specific peptide in
one individual. The significance between two groups was calculated by Mann–Whitney U-test; *, p < 0.05.
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position affording clear viral advantage in at least some
cases.
We therefore propose the following model of HLA-
A*24:02-mediated CTL targeting of these overlapping
Nef epitopes in vivo. If an HLA-A*24:02-expressing pa-
tient were to be infected with the wild type virus, CTL
responses would first arise against Nef134-10, eliciting
the Y135F escape mutant. This in turn would reveal the
novel Nef126-10 epitope, against which CTL responses
would then arise. Similarly, if an HLA-A*24:02 express-
ing patient were to be infected with a virus harboring
Y135F (a likely occurrence given its extremely high
prevalence in Japan), we infer that a CTL response
against Nef126-10 epitope would be launched immedi-
ately following infection.
As such HIV’s evasion of Nef134-10-specific CTL
(either via transmission or in vivo selection of Y135F)
yields a major, albeit temporary advantage to HIV, that is
subsequently diminished by the creation of the Nef126-10epitope that is then targeted in most A*24:02-expressing
persons. By extension, the “epitope switching” from
Nef134-10 to Nef126-10 may contribute in part to the
previous observation of relatively stable pVL over time
among HLA-A*24:02 positive patients [26] despite high
transmission frequency of 135F [4]. These observations
are not inconsistent with the idea that population-level
HIV adaptation to HLA could lead to weakening of host
antiviral control if “HLA-adapted” forms dominated the
population (as is the case with Nef-135F in Japan, which
represents the consensus at this position) [27]. If the con-
sensus at Nef codon 135 was the susceptible Y rather than
the escaped F in Japan, we hypothesize that control of
HIV by A*24 would be even greater in this region, as
Nef134–10 and Nef126-10 would be sequentially tar-
geted (rather than just Nef126-10 in the case where
135F is acquired at transmission).
Of note, among the 46 patients in the IMSUT cohort,
there were no significant differences in plasma HIV load
between patients with or without Nef126-10-specific
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However, this observation should be interpreted in the
context that all patients responding to Nef126-10 responses
harbored Nef-135F (that confers escape from responses
against the downstream Nef134-10 epitope). Moreover,
the observation that no reversion of 135F to 135Y was
ever observed in Nef126-10 responders (Figure 1C) sug-
gests that Nef126-10-specific CTL responses are not as
effective as Nef134-10-specific ones in controlling HIV
in vivo. Elucidating the mechanisms and in vivo relevance of
our observations would be crucial for vaccine development.
Among the HLA-associated polymorphisms, amino acid
substitutions between K-R, E-D, V-I, I-L, and Y-F are rela-
tively frequent [8,24,25]. The similarities of these amino
acid residue pairs with respect to size, charge, hydrophobi-
city, and other biochemical properties suggest that they
are often critical to the structure and function of the viral
proteins involved. Although in the present study we
characterized an example of escape-induced “epitope
switching” in HIV-1, we do not know how often this
phenomenon occurs. If an HLA-driven escape mutation
has the potential to serve as an anchor of a cryptic epi-
tope, and if an N-terminal or C-terminal anchor residue
is present at a proper distance, incorporation of both
the wild-type and the mutant peptide in a vaccine may
elicit immune response to that cryptic epitope. The
vaccine-induced CTL repertoire may be useful following
selection of the escape mutant or may prevent its selection
altogether. As such, the phenomenon of escape-induced
“epitope switch” may be relevant to vaccine design.
Conclusions
Our data represent the first example of the de novo
creation of a novel overlapping CTL epitope as a direct
result of HLA-driven immune escape in a neighboring
epitope. The robust targeting of Nef126-10 following
transmission (or in vivo selection) of HIV-1 containing
Y135F may explain in part the previously reported stable
plasma viral loads over time in the Japanese population,
despite the high prevalence of both HLA-A*24:02 and
Nef-Y135F in circulating HIV-1 sequences.
Methods
Patients and samples
The samples and host/viral genotype data analyzed in this
study were obtained from three independent sources: (i)
the IMSUT cohort at the Institute of Medical Science, the
University of Tokyo, Japan, (ii) the baseline (pre-therapy)
cross-section of the HOMER cohort in British Columbia,
Canada ([8] and unpublished), and (iii) a longitudinal
multicenter cohort of acute/early infected individuals
[28]. The IMSUT cohort, which consists primarily of
Asian patients with chronic infection, was used to de-
termine the viral sequences and immune responses.IMSUT cohort
Forty-six HLA-A*24:02-positive, antiretroviral-naïve,
chronically HIV-infected subjects were selected from
among patients participating in an ongoing HIV-1-
immunopathogenesis study at an HIV outpatient clinic
affiliated with the Institute of Medical Science, the
University of Tokyo (IMSUT). Study procedures in-
cluded routine collection of blood samples for virologic
and immunologic testing. Peripheral blood mononuclear
cells (PBMCs) and plasma samples were separated and
preserved in liquid nitrogen or at −80°C, respectively,
until use. The study was approved by the internal re-
view board of the Institute of the Medical Science of the
University of Tokyo (No. 11–2), and all subjects were
adults and provided written informed consent.
HOMER cohort
A total of 1038 patients from the HAART Observational
Medical Evaluation and Research (HOMER) cohort, an
open cohort of initially antiretroviral-naïve chronically
HIV-infected individuals in British Columbia, Canada of
predominantly Caucasian ethnicity, were analyzed in the
present study. Plasma HIV-1 RNA sequencing and HLA
class I sequence-based typing were performed as previ-
ously described [8]. We applied phylogenetically-corrected
methods [25] to determine the strength of association
between amino acid variants at Nef codons 133 and 135 in
this dataset.
Longitudinal acute/early infection cohort
Kaplan-Meier analysis was used to investigate the time
course of selection of specific immune escape muta-
tions at Nef codons 133 and 135 among 16 HLA-A*24
expressing individuals from a longitudinal, multicen-
ter, acute/early HIV-1 infection cohort [28]. “Time to
escape” was defined as the number of days elapsed
between estimated infection date and first detection
of the escape variant (as a full or partial amino acid
change).
Plasma viral RNA sequences
Viral RNA was extracted from 140 μl of plasma using the
QIAamp viral RNA Mini kit (QIAGEN). Using 4 μl of
RNA as starting material, reverse transcription and first
PCR were carried out according to the manufacturer’s
protocol with SuperScript III One-Step RT-PCR System
with Platinum Taq High Fidelity (Invitrogen). Two μl of the
first PCR product was subjected to nested PCR, performed
using Ex-Taq HS (Takara) with 35 cycles of 30s at 94°C, 30s
at 55°C, 60s at 72°C and a final extension for 7 min at 72°C.
The primer sets were as follows (Nucleotide positions are
those of the published HIV-1 SF2 strain (GenBank acces-
sion number: K02007). For the first PCR, primers Nef-1F
(5’-GTAGCTGAGGGGACAGATAGGGTTAT-3’) (nt 8,6
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TTATTGAGGC-3’) (nt 9,632 to 9,607) were used; and for
the nested PCR, primers Nef-2F (5’-CGTCTAGAACAT
ACCTAGAAGAATAAGACAGG-3’) (nt 8,746 to 8,777)
and Nef-2R (5’-CGGAATCCGTCCCCGCGGAAAGTCCC
TTGTA-3’) (nt 9,477 to 9,444) were used. The PCR prod-
ucts were purified with a PCR purification kit (QIAGEN)
before sequencing. DNA sequencing was performed
using an ABI Prism dye terminator cycle sequencing-
ready reaction kit (Applied Biosystems) on a Perkin-
Elmer ABI-377 sequencer.Expression vectors
To construct the HLA-A*24:02 expression vector,
pcDNA3.1-A24-DsRedm, the HLA-A*24:02 sequence was
amplified by PCR using cloned HLA-A*24:02 cDNA as a
template [29,30] and digested with BamHI and NcoI.
Primers (5’-TAATACGACTCACTATAGGG-3’) and
(5’-CCATGGATCCGCCCCCTCCCACTTTACAAGCTGT
GAGAGACAC-3’) were used for the amplification. The
pDsRed-Monomer (Clontech) sequence was digested by
NcoI and NotI, and was ligated to the 3’ end of HLA-
A*24:02 fragment to obtain the HLA-A24-DsRedm frag-
ment. Then HLA-A24-DsRedm fragment was inserted
into the multiple cloning site of pcDNA3.1/Hygro(+)
vector (Invitrogen).
Mini-Nef and mini-Gag gene expression vectors con-
taining two reporter genes, renilla luceferase (Rluc) and
EGFP, together with hygromycin selection were con-
structed in a pTracer-CMV2 vector (Invitrogen) as fol-
lows. Wild-type and mutant mini-Nef genes (from amino
acid position 123 to 153) were amplified by PCR using the
plasmids containing HIV-1 SF-2 Nef gene with wild-type
or mutant sequence as a template [4,31,32]. Primer
sequences were (5’-GGTACCGCCGCCATGGATTGG-
CAGAATTACACA-3’) and (5’-GGATCCGCCCCCTC
CTACCTTCTCTGGCTC-3’). A mini-Gag gene, extend-
ing from amino acid position 18 to 46 in p17, which
includes the HLA-A*24:02-restricted CTL epitope Gag28-9
(KYRLKHIVW), was amplified using a plasmid contain-
ing the 5’ half of the HIV-1 SF2 strain [31,32]. The
primers used were 5’-GGTACCGCCGCCATGAAAAT
TCGGTTAAGG-3’ and 5’-GGATCCGCCCCCTCCGA
CTGCGAATCGTTC-3’. The Rluc and hygromycin genes
were amplified from pGL4.77 hRlucP/Hygro (Promega)
using primers 5’-GGATCCATGGCTTCCAAGGTGTA
C-3’ and 5’-TCTAGAGTCGCGGCCTTAGACGTT-3’.
KpnI/BamHI fragments of mini-Nef or mini-Gag, BamHI/
XbaI fragment of Rluc and hygromycin genes amplified
from pGL4.77 hRlucP/Hygro were ligated to the KpnI/
XbaI fragment of pTracer-CMV2 vector (Invitrogen)
to create a mini-Nef or mini-Gag expression vector,
pmNef(wt)-hRluc-EGFP and pmGag(wt)-hRluc-EGFP,respectively. In the final step the GFPz sequence was re-
placed by EGFP sequence (Clontech).
Peptides
Synthetic peptides were purchased from Sigma-Genosys.
The peptides used in the screening of immune response by
ELISpot had a purity of 70% or more. All other peptides
were more than 95% pure as determined by high-perform-
ance liquid chromatography and mass spectroscopy.
Cells and media
T2-A24, a kind gift from K. Kuzushima, was cultured in
RPMI 1640 (Sigma) supplemented with 100 U of penicil-
lin/ml, 100 U of streptomycin/ml, 10% heat-inactivated
fetal calf serum (FCS) (Sigma), and 0.8 mg of G418
(Invitrogen)/ml [33]. We established Nef126-10 and
Nef134-10-specific CTL clones, I30-1 and H27-9, as
previously described [18]. CTL clones were cultured with
RPMI 1640 supplemented with 50 U of interleukin-2/ml,
100U of penicillin/ml, 100U of streptomycin/ml, and 10%
heat-inactivated FCS (R10/50), but the clones were
cultured in the absence of interleukin-2 (R10) for two
days before antigen presentation assays. pcDNA3.1-
A24-DsRedm was introduced into 293FT cell line (Invi-
trogen) and the cells were treated by hygromycin for
2 weeks. After cloning by limiting dilution we obtained
293FT-A24DRm-CY0, and confirmed HLA-A*24:02 ex-
pression with FACS analysis by using anti-HLA-A9
serotype antibody (One Lambda, data not shown).
IFN-γ ELISpot assay
The gamma interferon enzyme-linked immunospot (IFN-
γ ELISpot) assay was performed using patients’ PBMCs as
previously described [4] with some modifications. In brief,
96-well plates (Millipore) were coated with anti-gamma-
interferon (IFN-γ) MAb 1-D1k (Mabtech) overnight at
4°C. Peptides were added directly to the wells at a final
concentration of 10−5 M. 5 ~ 10 × 104 cells were added to
each well with a final volume of 100 μl of R10. For nega-
tive controls, PBMCs were incubated with R10 alone with-
out peptides. After incubation at 37°C under 5% CO2
overnight (16 to 18 h), the plates were washed six times
with phosphate-buffered saline containing 0.01% tween-20
(PBST). Biotinylated anti-IFN-γ MAb 7-B6-1 (Mabtech)
was added, and was incubated for 2 hours at 37°C under
5% CO2. After washing with PBST, streptavidin-alkaline
phosphatase conjugate (Mabtech) was added and the
plates were kept at room temperature for 45 min. After
washing with PBST, IFN-γ-producing cells were detected
as dark spots after 10- to 20-min color reaction with
5-bromo-4-chloro-3-indolylphosphate and nitroblue tetra-
zolium by using AP Conjugate Substrate Kit (Bio-Rad).
Spots were counted by KS ELISPOT compact (Carl Zeiss)
and expressed as spot-forming units (SFU) per 106 PBMCs
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Values with >50 SFU, >3 ×mean SFU of negative control
and >mean SFU of negative control + 3 SD per 106 input
cells were considered as a positive response.
Since more cells were required for the immune
response screening (Figure 1B) and functional avidity
assays (Figures 4B and 6C), PBMCs were stimulated
with anti-human CD3 antibody and the T cells were
expanded for 2 to 3 weeks in R10/50 (BD Pharmingen).
Culture media was changed to R10 two days prior to the
assay date. For ex vivo IFN-γ ELISpot assay (Figures 5B
and 6B), PBMCs were cultured for 6 hours in R10 media.
Peptide-HLA binding assay (Figure 2A)
Peptide binding to HLA-A*24:02 was assessed by using
a T2-A24 stabilization assay as previously described [4,33].
Briefly, after incubation for 16 hours at 26°C under 5%
CO2, 2 × 10
5 T2-A24 cells were incubated with 10−4 to
10−9 M peptides for 1 h at 4°C. After keeping at 37°C
under 5% CO2 for 3 hours, the cells were stained with
biotinylated anti-human HLA-A9 monoclonal antibody
(One Lambda), and streptavidin-APC conjugates (BD
Pharmingen). The mean fluorescence intensity (MFI)
was measured by FACSCalibur (Becton Dickinson). In
each experiment, MFI of samples was normalized by the
MFI of 10−4 M control peptide, Nef134-8(RYPLTFGW).
Three independent experiments were performed.
CTL clones and Epitope recognition (Figure 2B)
Nef134-10- and Nef126-10-specific clones, H27-9 and
I30-1, were established by Nef134-10(wt) and Nef126-10
(wt) peptide stimulation respectively, and limiting dilu-
tion of PBMCs from HIV-1-infected patients harboring
133 T/135 F. For in-vitro peptide stimulation, 5 × 105
PBMCs were pulsed with 10 μM of each peptide for 1 h.
The cells were washed twice with R10, then cultured
with 1 × 106 autologous PBMCs and 4 × 106 irradiated
(3300 rad) allogeneic PBMCs in R10. After 4 days, IL-2
was added to 50 U/ml and the cells were cultured for
2–3 weeks in R10/50. Peptide-specific CD8+ T cells were
enriched by MACS separation (Miltenyi) using tetra-
mers. The sorted cells were cloned by limiting dilution
to 3 or 10 cells/well in 96-well round-bottom tissue cul-
ture plates, and cultured with 105 irradiated allogeneic
PBMCs in R10/50 containing 5 μg/ml PHA-L.
CTL-recognition of the epitopes was assessed by seri-
ally diluted peptides. On day 0, 293FT-A24DRm-CY0
cells were seeded onto 96-well Flat-bottom transparent
plate (BD Falcon) so that the cultures become confluent
on day 2. On day 2, each peptide was pulsed with concen-
trations from 32 to 3−6 μM to the wells and incubated at
37°C under 5% CO2 for 1 h. Then CTLs (5,000 ~ 10,000
cells) were added and co-cultured at 37°C under 5% CO2
for 18 to 24 h. After the incubation, supernatants wereharvested, and IFN-γ concentrations were quantified by
Human IFN-γ ELISA Set (BD Bioscience). In each experi-
ment, the IFN-γ value of samples was normalized to that
of the highest wild type peptide concentration (9 μM). For
example, each IFN-γ value of I30-1 CTL clone was divided
by the value of the well pulsed with 9 μM Nef126-10(wt)
peptide. Each assay was performed in duplicate and three
independent experiments were conducted.
Antigen presentation assay (Figure 3)
Antigen presentation was assessed by measuring epitope-
specific CTL responses to endogenously expressed anti-
gen. First, intracellular expression of each antigen was
extrapolated from the activity of reporter protein, Rluc.
293FT-A24DRm-CY0 cells were seeded in 96-well plate
(Nunc) on day 0. On day 1, antigen expression plasmids,
pmNef(wt)-hRluc-EGFP, pmNef(135F)-hRluc-EGFP, pmNef
(133T135F)-hRluc-EGFP, or control vectors (pmGag(wt)-
hRluc-EGFP) were transfected into the cells in each
well using FuGENE HD (Promega). The cultures were
incubated at 37°C under 5% CO2 for 18 to 24 h. On day 2,
transfection efficiency was inspected roughly under a
fluorescence microscope (KEYENCE BZ-9000), then
Rluc activity in each transfected well was measured by
using Dual-Glo Luciferase Assay System (Promega) and
luminometer (Promega GloMax 96 Microplate Lumin-
ometer). The assay was performed in triplicate.
Second, CTL responses against endogenously expressed
and processed epitopes were evaluated. 293FT-A24DRm-
CY0 cells were seeded onto a 96-well Flat-bottom trans-
parent plate (BD Falcon) on day 0. On day 1, expression
plasmid was transfected to each well using FuGENE HD
(Promega). CTLs (5,000 ~ 10,000 cells) were added to the
transfected wells on day 2. After incubation for 18 to 24 h,
the supernatant of each well was harvested, and IFN-γ
secretion was quantified by Human IFN-γ ELISA Set (BD
Bioscience). IFN-γ ELISA was performed in duplicate.
Experiments were performed in duplicate on three
independent occasions. To normalize the values in each
experiment, mean IFN-γ values of each sample were
normalized by the mean value of reference wells in
duplicate. In the reference wells, 9 μM of the wild type
peptide was pulsed to the antigen presenting cells and
then co-cultured with CTLs.
Protein expression in E. coli, refolding and purification
HLA-A*24:02 and β2m were expressed in E. coli and
refolded from inclusion bodies as previously described
with some modifications [34]. HLA-A*24:02 (18 mg), β2m
(6 mg) and peptide (4 mg) were mixed in 400 ml of refold
buffer containing 100 mM Tris, pH 8.0, 400 mM L-ar-
ginine-HCl, 2 mM EDTA, 5 mM GSH, 0.5 mM GSSG,
0.2 mM PMSF. The refolded protein was purified by
Superdex 75 column, followed by Mono Q column, and
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pH 8.0, 50 mM NaCl for crystallization.
Crystallization, data collection and structure
determination
The crystallization was done by the sitting drop vapor
diffusion method at 20°C. Crystals of the A24/N126-10
(8T10F) complex were obtained in 20% (w/v) PEG 3350,
200 mM sodium phosphate dibasic, and those of A24/
N126-10(8I10F) were obtained in 20% (w/v) PEG 3350,
200 mM sodium nitrate. For cryoprotection, crystals were
soaked briefly in reservoir solutions containing 20% ethyl-
ene glycol, and then frozen in liquid nitrogen before data
collection. Data were collected at the beamline BL41XU in
SPring 8 (Hyogo, Japan), and processed with HKL2000
[35] and the CCP4 program suite [36].
The structure were determined by molecular replace-
ment using Molrep [37]. The search model was the
coordinate file of PDB (Protein Data Bank) code 3I6L
with omitted peptide for A24/N126-10(8T10F). Model
building and refinement were carried out using Coot
[38] and REFMAC5.6 implemented in CCP4, respect-
ively. The structure of A24/N126-10(8I10F) was deter-
mined with the refined A24/N126-10(8T10F) as a search
model and refined as described above. The stereochem-
istry of the refined models was assessed with RAMPAGE
[39]. All molecular graphic representations were created
with the program PyMOL (DeLano Scientific; http://
www.pymol.org). Data collection and refinement statis-
tics are shown in Additional file 2: Table S1.
Functional avidity assay
Basically, the assay was performed using the same pro-
cedure with IFN-γ ELISpot assay as described above.
PBMCs were cultured for 2 to 3 weeks in R10/50 after
anti-human CD3 antibody (BD Pharmingen) stimulation,
and culture media were changed from R10/50 to R10 two
days before use. PBMCs were incubated with peptides at
concentrations from 10−5 to 10−12 M, and SFU was cal-
culated. The functional avidity to peptide dilutions was
determined as a 50% of sigmoidal dose (SD50) SFU.
Statistical analysis
All data visualization and statistical analyses were per-
formed using GraphPad Prism (GraphPad Software, La
Jolla, CA). Student’s t-test and Mann–Whitney U-test
were used to compare the antigen presentation and func-
tional avidity between two groups, respectively. Spearman
rank correlation was used to calculate the correlation
between peptide-specific response and pVL. Dose at
50% response in sigmoidal dose–response curves (SD50)
was calculated by drawing sigmoidal dose–response
curves. Time to mutational escape, defined as the time
elapsed between estimated date of HIV-1 infection andthe first appearance of a full or partial amino acid
change consistent with the specific escape mutation of
interest, was calculated using Kaplan-Meier (survival)
methods.Additional files
Additional file 1: Figure S1. Overview of structures of the HLA-A*2402
in complex with the Nef126-10 peptides. Structures of (A) the A24/N126-10
(8I10F) and (B) the A24/N126-10(8T10F).The electron density of (C) the
Nef126-10(8I10F) and (D) the Nef126-10(8T10F) are shown with Fo-Fc omit
maps contoured at 2.0 σ (cyan mesh). (C and D) The peptide structures are
shown in a side view (top panels) and top view (bottom panels). The
Nef126-10 (8I10F) and the Nef126-10 (8T10F) are shown as a purple and a
green stick model, respectively. HLA-A24 and β2m are represented as gray
and black cartoon model, respectively.
Additional file 2: Table S1. Data collection and refinement statistics.
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